Notice: You are viewing a basic version of this page. Are you using a very old browser? If so, please consider upgrading


Resources

Information Leaflets and Resources

Site staff training resources

Thumbnail preview of the file.
MAMA SIV Training Slides

Eligibility check tools

Please use the following tools to check whether:

  • The regularly dosed biologic for RA, JIA, PsA or axSpA that a woman has been prescribed is a biologic which is included in MAMA
  • (If applicable) the country that a woman plans to move in the first 6 months after birth with their infant has a high rate of tuberculosis (incidence >40 per 100,000 population)

List of regularly dosed biologic (including the listed reference medicinal product and biosimilars) for RA, JIA, PsA, or axSpA

If you cannot find the drug a woman has been prescribed in this list please contact the MAMA Study Team.

Source: MAMA IMP List Reference Drugs and Biosimilars v1.0 13Nov2024

Drug name:

  • Humira
  • Amgevita
  • Hyrimoz
  • Idacio
  • Imraldi
  • Yuflyma
  • Enbrel
  • Benepali
  • Erelzi
  • Remicade
  • Flixabi
  • Inflectra
  • Remsima
  • Zessly
  • Simponi
  • Cimzia
  • Orencia
  • RoActemra
  • Tyrenne
  • Kevzara
  • Kineret
  • Ilarus
  • Cosentyx
  • Taltz
  • Bimzelx
  • Tremfya
  • Skyrizi
  • Stelara
  • Pyzchiva
  • Steqeyma
  • Uzpruvo
  • Wezenla

List of countries with a high rate of tuberculosis (incidence >40 per 100,000 population)

If a woman plans to move with her infant to live in one of the countries on this list in the first 6 months after birth she is not eligible for the MAMA Study.

Source: Countries with over 40 per 100K TB, 2022 - WHO

Country:

  • Afghanistan
  • Algeria
  • Angola
  • Azerbaijan
  • Bangladesh
  • Benin
  • Bhutan
  • Bolivia (Plurinational State of)
  • Botswana
  • Brazil
  • Brunei Darussalam
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Central African Republic
  • Chad
  • China
  • China, Hong Kong SAR
  • China, Macao SAR
  • Colombia
  • Congo
  • Cote d'Ivoire
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Djibouti
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Eswatini
  • Ethiopia
  • Fiji
  • Gabon
  • Gambia
  • Georgia
  • Ghana
  • Greenland
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • India
  • Indonesia
  • Kazakhstan
  • Kenya
  • Kiribati
  • Kyrgyzstan
  • Lao People's Democratic Republic
  • Lesotho
  • Liberia
  • Libya
  • Madagascar
  • Malawi
  • Malaysia
  • Mali
  • Marshall Islands
  • Mauritania
  • Micronesia (Federated States of)
  • Mongolia
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Northern Mariana Islands
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Republic of Moldova
  • Romania
  • Rwanda
  • Sao Tome and Principe
  • Senegal
  • Sierra Leone
  • Singapore
  • Solomon Islands
  • Somalia
  • South Africa
  • South Sudan
  • Sri Lanka
  • Sudan
  • Tajikistan
  • Thailand
  • Timor-Leste
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Republic of Tanzania
  • Uzbekistan
  • Venezuela (Bolivarian Republic of)
  • Viet Nam
  • Yemen
  • Zambia
  • Zimbabwe

Updated: Friday, 19 December 2025 12:18 (v12)

Contact us

If you would like more information or are interested in taking part in the MAMA Study, please get in touch with the team at the MAMA Co-ordinating Centre.